688266 泽璟制药-U
已收盘 06-02 15:00:00
资讯
新帖
简况
泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%
证券之星 · 06-01 22:15
泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%
股市必读：泽璟制药（688266）5月29日披露最新机构调研信息
证券之星 · 06-01 03:42
股市必读：泽璟制药（688266）5月29日披露最新机构调研信息
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点
证券之星 · 05-10
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点
泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%
证券之星 · 05-08
泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%
每周股票复盘：泽璟制药（688266）Q1净利增2338%
证券之星 · 05-02
每周股票复盘：泽璟制药（688266）Q1净利增2338%
图解泽璟制药一季报：第一季度单季净利润同比增长2338.37%
证券之星 · 04-28
图解泽璟制药一季报：第一季度单季净利润同比增长2338.37%
每周股票复盘：泽璟制药（688266）将参加2026年5月11日科创板集体业绩说明会
证券之星 · 04-26
每周股票复盘：泽璟制药（688266）将参加2026年5月11日科创板集体业绩说明会
泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%
证券之星 · 04-23
泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%
泽璟制药（688266）披露股东及董事、高级管理人员减持股份结果公告，4月20日股价上涨1.21%
证券之星 · 04-20
泽璟制药（688266）披露股东及董事、高级管理人员减持股份结果公告，4月20日股价上涨1.21%
每周股票复盘：泽璟制药（688266）高管与股东减持股份
证券之星 · 04-19
每周股票复盘：泽璟制药（688266）高管与股东减持股份
泽璟制药：4月16日董事长ZELIN SHENG(盛泽林)减持股份合计27.39万股
证券之星 · 04-17
泽璟制药：4月16日董事长ZELIN SHENG(盛泽林)减持股份合计27.39万股
泽璟制药（688266）披露2025年度持续督导跟踪报告，4月16日股价上涨1.19%
证券之星 · 04-16
泽璟制药（688266）披露2025年度持续督导跟踪报告，4月16日股价上涨1.19%
泽璟制药的“尴尬成年礼”：营收破8亿，亏损却扩大了
新浪证券 · 04-10
泽璟制药的“尴尬成年礼”：营收破8亿，亏损却扩大了
泽璟制药(688266.SH)获得药物临床试验批准通知书
智通财经 · 04-08
泽璟制药(688266.SH)获得药物临床试验批准通知书
股市必读：泽璟制药（688266）4月3日披露最新机构调研信息
证券之星 · 04-07
股市必读：泽璟制药（688266）4月3日披露最新机构调研信息
【机构调研记录】金信基金调研泽璟制药
证券之星 · 04-06
【机构调研记录】金信基金调研泽璟制药
【机构调研记录】格林基金调研芯动联科、泽璟制药等3只个股（附名单）
证券之星 · 04-06
【机构调研记录】格林基金调研芯动联科、泽璟制药等3只个股（附名单）
每周股票复盘：股东减持95.45万股，泽璟制药（688266）多款新药推进商业化
证券之星 · 04-05
每周股票复盘：股东减持95.45万股，泽璟制药（688266）多款新药推进商业化
泽璟制药（688266）披露持股5%以上股东权益变动触及1%刻度的提示性公告，4月3日股价下跌2.64%
证券之星 · 04-03
泽璟制药（688266）披露持股5%以上股东权益变动触及1%刻度的提示性公告，4月3日股价下跌2.64%
4月2日泽璟制药发布公告，股东减持95.46万股
证券之星 · 04-02
4月2日泽璟制药发布公告，股东减持95.46万股
加载更多
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是创新型小分子及生物制剂疗法的发现、研发及商业化。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。在血液病及止血领域，泽普凝为中国唯一采用重组DNA技术研发并成功上市的重组人凝血酶。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药-U","latestPrice":96.26,"timestamp":1780383600000,"preClose":99.62,"halted":0,"volume":3468378,"delay":0,"changeRate":-0.0337,"floatShares":265000000,"shares":265000000,"eps":1.8811,"marketStatus":"已收盘","change":-3.36,"latestTime":"06-02 15:00:00","open":100,"high":100,"low":95,"amount":335000000,"amplitude":0.0502,"askPrice":96.27,"askSize":3,"bidPrice":96.26,"bidSize":5,"shortable":0,"etf":0,"ttmEps":1.8811,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780450200000},"marketStatusCode":5,"adr":0,"adjPreClose":99.62,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780363800000,1780371000000],[1780376400000,1780383600000]],"highLimit":109.58,"lowLimit":89.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":14.87,"roa":"--","peRate":51.172186,"roe":"45.29%","epsLYR":-0.62,"committee":0.513043,"marketValue":25481000000,"turnoverRate":0.0131,"status":1,"afterMarket":{"amount":0,"volume":0,"close":96.26,"buyVolume":0,"sellVolume":0,"time":1780385638866,"indexStatus":"已收盘 06-02 15:30:00","preClose":99.62},"floatMarketCap":25481000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2640898950","title":"泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640898950?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:15","pubTimestamp":1780323318,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，泽璟制药报收于99.62元，较前一交易日下跌0.31%，最新总市值为263.7亿元。近日，泽璟制药发布《关于召开2025年年度股东会的通知》。公告显示，苏州泽璟生物制药股份有限公司将于2026年6月26日召开2025年年度股东会，会议采取现场投票与网络投票相结合的方式，股权登记日为2026年6月22日。会议审议包括2025年年度报告、董事会工作报告、利润分配预案、续聘2026年度审计机构、董事薪酬标准及薪酬管理制度等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100040858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640851849","title":"股市必读：泽璟制药（688266）5月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2640851849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640851849?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:42","pubTimestamp":1780256530,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，泽璟制药报收于99.93元，上涨3.23%，换手率1.72%，成交量4.54万手，成交额4.41亿元。当日关注点来自交易信息汇总：5月29日主力资金净流入448.35万元，占总成交额1.02%。来自机构调研要点：泽璟制药将在2026年ASCO年会公布ZG005联合贝伐珠单抗用于晚期肝细胞癌一线治疗的Ⅱ期临床研究数据，该研究入选大会口头报告。注射用ZG006联合瀚森制药HS-20093治疗广泛期小细胞肺癌的临床试验已获国家药监局批准，公司正推进合作事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634741496","title":"每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2634741496","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634741496?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:29","pubTimestamp":1778351350,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：注射用人促甲状腺素β III期临床试验达到预设主要终点。公司公告汇总泽璟制药关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告苏州泽璟生物制药股份有限公司自主研发的注射用人促甲状腺素βIII期临床试验达到预设主要终点，该试验用于评价其在分化型甲状腺癌患者术后放射性碘清甲治疗的有效性和安全性。注射用人促甲状腺素β已于2026年1月获批用于甲状腺癌术后随访中的协同诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633300431","title":"泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633300431","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633300431?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:35","pubTimestamp":1778232935,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告》。公告显示，苏州泽璟生物制药股份有限公司自主研发的注射用人促甲状腺素βIII期临床试验达到预设主要终点，该试验用于评价其在分化型甲状腺癌患者术后放射性碘清甲治疗的有效性和安全性。注射用人促甲状腺素β已于2026年1月获批用于甲状腺癌术后随访中的协同诊断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632420036","title":"每周股票复盘：泽璟制药（688266）Q1净利增2338%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632420036","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632420036?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:06","pubTimestamp":1777665974,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，泽璟制药报收于104.0元，较上周的97.1元上涨7.11%。本周，泽璟制药4月30日盘中最高价报108.73元。股本股东变化截至2026年3月31日，泽璟制药股东户数为8344.0户，较2月28日减少1685.0户，减幅为16.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630237034","title":"图解泽璟制药一季报：第一季度单季净利润同比增长2338.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630237034","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630237034?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:23","pubTimestamp":1777371783,"startTime":"0","endTime":"0","summary":"证券之星消息，泽璟制药2026年一季报显示，一季度公司主营收入9.05亿元，同比上升440.07%；归母净利润6.33亿元，同比上升2338.37%；扣非净利润6.32亿元，同比上升1362.4%；负债率53.56%，投资收益3.45万元，财务费用-111.81万元，毛利率97.01%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804451","title":"每周股票复盘：泽璟制药（688266）将参加2026年5月11日科创板集体业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804451?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:54","pubTimestamp":1777146851,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，泽璟制药报收于97.1元，较上周的98.8元下跌1.72%。本周，泽璟制药4月20日盘中最高价报103.66元。本周关注点公司公告汇总：泽璟制药将参加2026年5月11日举行的科创板集体业绩说明会。投资者可于2026年4月29日至5月8日16:00前通过上证路演中心网站或公司邮箱提前提问。公司将就2025年年度报告涉及的经营成果、财务状况等投资者关注问题进行解答。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830726","title":"泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830726","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830726?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:05","pubTimestamp":1776953123,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，泽璟制药报收于98.0元，较前一交易日下跌3.14%，最新总市值为259.41亿元。近日，泽璟制药发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00通过上证路演中心网络互动方式参加由上海证券交易所主办的上述集体业绩说明会。公司将就2025年年度报告涉及的经营成果、财务状况等投资者关注问题进行解答。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300061779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK1574","BK0239","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628746118","title":"泽璟制药（688266）披露股东及董事、高级管理人员减持股份结果公告，4月20日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628746118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628746118?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:32","pubTimestamp":1776677526,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，泽璟制药报收于100.0元，较前一交易日上涨1.21%，最新总市值为264.71亿元。公司于近日披露《股东及董事、高级管理人员减持股份结果公告》。公告显示，本次减持计划实施前，ZELIN SHENG（盛泽林）持有公司18.8549%股份，宁波泽奥持有6.2335%股份。2026年2月14日，公司披露减持计划，ZELIN SHENG（盛泽林）拟减持不超过273,907股，宁波泽奥拟减持不超过2,475,090股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000024454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628759721","title":"每周股票复盘：泽璟制药（688266）高管与股东减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628759721","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628759721?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:12","pubTimestamp":1776539529,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，泽璟制药报收于98.8元，较上周的97.77元上涨1.05%。本周，泽璟制药4月16日盘中最高价报102.87元。泽璟制药当前最新总市值261.53亿元，在化学制药板块市值排名16/150，在两市A股市值排名832/5198。股本股东变化：宁波泽奥创业投资合伙企业减持247.51万股，持股比例降至5.2985%。股本股东变化股东增减持4月17日公告显示，宁波泽奥创业投资合伙企业于2026年4月2日至4月15日期间合计减持152.05万股，占公司总股本的0.5744%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628120829","title":"泽璟制药：4月16日董事长ZELIN SHENG(盛泽林)减持股份合计27.39万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628120829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628120829?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:01","pubTimestamp":1776423664,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月17日市场公开信息、上市公司公告及交易所披露数据整理，泽璟制药最新董监高及相关人员股份变动情况：2026年4月16日公司董事长,总经理ZELIN SHENG(盛泽林)共减持公司股份27.39万股，占公司总股本为0.1035%。泽璟制药近半年内的董监高及核心技术人员增减持详情如下：泽璟制药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入616.97万，融资余额增加；融券净流出2112.0，融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700037890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627958295","title":"泽璟制药（688266）披露2025年度持续督导跟踪报告，4月16日股价上涨1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627958295","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627958295?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:17","pubTimestamp":1776331043,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，泽璟制药报收于101.5元，较前一交易日上涨1.19%，最新总市值为268.68亿元。该股当日开盘100.8元，最高102.87元，最低97.8元，成交额达2.99亿元，换手率为1.12%。泽璟制药于2026年4月16日披露《中国国际金融股份有限公司关于苏州泽璟生物制药股份有限公司2025年度持续督导跟踪报告》。报告指出，2025年公司营业收入同比增长52.07%，主要因药品销量增长；净利润亏损扩大；研发投入持续增加；公司未发生重大违规事项，募集资金使用合规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600031179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626191750","title":"泽璟制药的“尴尬成年礼”：营收破8亿，亏损却扩大了","url":"https://stock-news.laohu8.com/highlight/detail?id=2626191750","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626191750?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:53","pubTimestamp":1775818380,"startTime":"0","endTime":"0","summary":"作为科创板首家以“未盈利”身份上市的生物医药企业，泽璟制药在2025年终于实现了四款产品全系纳入医保、年营收突破8亿元的历史性跨越。这家曾经被誉为“国产创新药希望之星”的公司，正在经历一场“增收不增利”的尴尬成年礼。 2025年，泽璟制药实现营业收入8.10亿元，同比增长52.07%，创下上市以来最高增速。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-10/doc-inhtzhty0252535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946688","title":"泽璟制药(688266.SH)获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946688","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625946688?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:59","pubTimestamp":1775649592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG006联合注射用HS-20093联合或不联合阿得贝利单抗注射液治疗广泛期小细胞肺癌的临床试验获得批准。根据国家药品注册相关的法律法规要求，药品在获得《药物临床试验批准通知书》后，尚需开展临床试验，并经国家药监局批准后方可上市销售。本次注射用ZG006联合注射用HS-20093联合或不联合阿得贝利单抗注射液治疗广泛期小细胞肺癌的临床试验获批事项对公司近期业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625603873","title":"股市必读：泽璟制药（688266）4月3日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2625603873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625603873?lang=zh_cn&edition=full","pubTime":"2026-04-07 01:20","pubTimestamp":1775496018,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，泽璟制药报收于99.5元，下跌2.64%，换手率0.99%，成交量2.62万手，成交额2.62亿元。宁波泽奥于2026年3月30日至4月1日通过集中竞价方式减持公司股份954,550股，占公司总股本的0.36%。本次权益变动后，宁波泽奥及其一致行动人持有公司股份比例由6.25%减少至5.89%，触及1%刻度。盐酸吉卡昔替尼片于2025年5月获批上市，2026年1月1日起纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700000590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625462501","title":"【机构调研记录】金信基金调研泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2625462501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625462501?lang=zh_cn&edition=full","pubTime":"2026-04-06 08:02","pubTimestamp":1775433763,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月3日披露的机构调研信息，金信基金近期对1家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：多纳非尼片截至2025年12月31日已进入医院1,300余家、覆盖医院2,350余家、覆盖药房1,000余家，2026年将继续扩大覆盖范围。金信基金成立于2015年，截至目前，资产管理规模149.48亿元，排名131/212；资产管理规模119.21亿元，排名116/212；管理公募基金数48只，排名109/212；旗下公募基金经理8人，排名121/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040600000285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625055625","title":"【机构调研记录】格林基金调研芯动联科、泽璟制药等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2625055625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625055625?lang=zh_cn&edition=full","pubTime":"2026-04-06 08:02","pubTimestamp":1775433743,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月3日披露的机构调研信息，格林基金近期对3家上市公司进行了调研，相关名单如下：1）芯动联科 调研纪要：2025年公司营业收入为52,374.07万元，同比增长29.48%，净利润同比增长36.91%。2026年研发费用预计将保持平稳或合理增长。格林基金成立于2016年，截至目前，资产管理规模248.65亿元，排名117/212；资产管理规模243.8亿元，排名99/212；管理公募基金数63只，排名95/212；旗下公募基金经理11人，排名103/212。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040600000254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0214","688582","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616585","title":"每周股票复盘：股东减持95.45万股，泽璟制药（688266）多款新药推进商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616585","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616585?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:57","pubTimestamp":1775325427,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，泽璟制药报收于99.5元，较上周的100.69元下跌1.18%。本周，泽璟制药4月1日盘中最高价报106.28元。本周关注点来自股本股东变化：股东宁波泽奥创业投资合伙企业减持95.45万股，占总股本0.3606%。该药已获中国国家药监局和FDA批准，进入I期临床试验。其于2026年3月30日至4月1日通过集中竞价减持954,550股，占总股本0.36%。权益变动后，宁波泽奥及其一致行动人持股比例由6.25%降至5.89%，触及1%刻度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668008","title":"泽璟制药（688266）披露持股5%以上股东权益变动触及1%刻度的提示性公告，4月3日股价下跌2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668008?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:14","pubTimestamp":1775225658,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，泽璟制药报收于99.5元，较前一交易日下跌2.64%，最新总市值为263.38亿元。泽璟制药于近日披露《关于持股5%以上股东权益变动触及1%刻度的提示性公告》。宁波泽奥于2026年3月30日至4月1日通过集中竞价方式减持公司股份954,550股，占公司总股本的0.36%。本次权益变动后，宁波泽奥及其一致行动人持有公司股份比例由6.25%减少至5.89%，触及1%刻度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624050619","title":"4月2日泽璟制药发布公告，股东减持95.46万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624050619","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624050619?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:01","pubTimestamp":1775131264,"startTime":"0","endTime":"0","summary":"证券之星消息，4月2日泽璟制药发布公告《泽璟制药:泽璟制药关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东宁波泽奥创业投资合伙企业(有限合伙)于2026年3月30日至2026年4月1日间合计减持95.45万股，占公司目前总股本的0.3606%，变动期间该股股价上涨3.39%，截止4月1日收盘报104.1元。股东增减持详情见下表：根据泽璟制药2025年年报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200037172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780401619415,"stockEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.3012},{"period":"6month","weight":-0.0717},{"period":"1year","weight":-0.084},{"period":"ytd","weight":0.0746}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0158},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2122},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8344人(较上一季度减少16.80%)","perCapita":"31724股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是创新型小分子及生物制剂疗法的发现、研发及商业化。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。在血液病及止血领域，泽普凝为中国唯一采用重组DNA技术研发并成功上市的重组人凝血酶。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药-U,688266,泽璟制药-U股票,泽璟制药-U股票老虎,泽璟制药-U股票老虎国际,泽璟制药-U行情,泽璟制药-U股票行情,泽璟制药-U股价,泽璟制药-U股市,泽璟制药-U股票价格,泽璟制药-U股票交易,泽璟制药-U股票购买,泽璟制药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}